926569-03-1

Basic information

• Product Name: 4-(((1R,4R)-4-hydroxycyclohexyl)amino)-3-nitrobenzonitrile
• Synonyms: 4-(((1R,4R)-4-hydroxycyclohexyl)amino)-3-nitrobenzonitrile
• CAS NO: 926569-03-1
• Molecular Weight: 261.28
• Mol File: 926569-03-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(((1R,4R)-4-hydroxycyclohexyl)amino)-3-nitrobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(((1R,4R)-4-hydroxycyclohexyl)amino)-3-nitrobenzonitrile(926569-03-1)
• EPA Substance Registry System: 4-(((1R,4R)-4-hydroxycyclohexyl)amino)-3-nitrobenzonitrile(926569-03-1)

Safety Data

• Hazardous Substances Data: 926569-03-1(Hazardous Substances Data)

Upstream product

• 1009-35-4 4-fluoro-3-nitrobenzonitrile 
• 6850-65-3 p-hydroxycyclohexylamine 
• 939-80-0 4-chloro-3-nitrobenzonitrile 
• 27489-62-9 trans-4-hydroxycyclohexylamine 

Downstream Products

• 1153524-64-1 3-amino-4-[(4-hydroxycyclohexyl)amino]benzonitrile 

Relevant articles and documents

Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion

RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.

Imidazopyridinone derivatives and their use as phosphodiesterase inhibitors

A compound (Ia): wherein the variables are defined in the specification, its prodrug or a pharmaceutically acceptable salt thereof useful in the treatment of angina, hypertension etc.